8QYR

Beta-cardiac myosin motor domain in the pre-powerstroke state complexed to Mavacamten

Summary for 8QYR

• Entry DOI: 10.2210/pdb8qyr/pdb
• Descriptor: Myosin-7, 6-[[(1~{S})-1-phenylethyl]amino]-3-propan-2-yl-1~{H}-pyrimidine-2,4-dione, SULFATE ION, ... (8 entities in total)
• Functional Keywords: cardiac myosin modulators inherited cardiomyopathies mavacamten, contractile protein
• Biological source: Bos taurus (cattle)
• Total number of polymer chains: 1
• Total formula weight: 90337.06

Authors

Robert-Paganin, J.,Kikuti, C.,Auguin, D.,Rety, S.,David, A.,Houdusse, A. (deposition date: 2023-10-26, release date: 2023-12-13)

Primary citation

Auguin, D.,Robert-Paganin, J.,Rety, S.,Kikuti, C.,David, A.,Theumer, G.,Schmidt, A.W.,Knolker, H.J.,Houdusse, A.
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite antagonistic effects in heart contraction.
Biorxiv, 2023

PubMed Abstract: Inherited cardiomyopathies are amongst the most common cardiac diseases worldwide, leading in the late-stage to heart failure and death. The most promising treatments against these diseases are small-molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Two of these molecules that produce antagonistic effects on cardiac contractility have completed clinical phase 3 trials: the activator and the inhibitor . In this work, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All atoms molecular dynamics simulations reveal how these molecules can have antagonistic impact on the allostery of the motor by comparing β-cardiac myosin in the apo form or bound to or . Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.

PubMed: 38014327
DOI: 10.1101/2023.11.15.567213

Experimental method

X-RAY DIFFRACTION (1.8 Å)